. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Eur J Cancer. 2019 Jul 17;118:58–66. doi: 10.1016/j.ejca.2019.05.033

Table 3.

Analysis of EFS and OS for 112 patients with stage 1 focal or diffuse anaplastic Wilms tumor treated on AREN0321 and NTWS 1–5 according to treatment and histologic subtype

Factor	Category	N	4-year EFS (95% CI)	P-value²	4-year OS (95% CI)	P-value²
Overall	-	112	83.8% (76.5–91.1)	-	89.3% (83.1–95.4)	-
Doxorubicin	Yes	36	97.2% (91.3–100)	0.01	97.2% (91.3–100)	0.10
Doxorubicin	No	76	77.5% (67.6–87.4)	0.01	85.5% (77.2–93.8)	0.10
Radiation	Yes	36	91.7% (81.7–100)	0.15	94.4% (86.2–100)	0.26
Radiation	No	76	80.2% (70.7–89.6)	0.15	86.8% (78.8–94.8)	0.26
Doxorubicin + radiation¹	Yes	33	97.0% (90.5–100)	0.03	97.0% (90.5–100)	0.14
Doxorubicin + radiation¹	No	73	79.4% (69.6–89.2)	0.03	86.2% (77.9–94.5)	0.14
Histology	DA	73	79.5% (69.7–89.2)	0.21	84.9% (76.2–93.5)	0.07
Histology	FA	39	92% (82.7–100)	0.21	97.4% (92–100)	0.07

EFS, Event -free survival; OS, overall survival; DA, diffuse anaplasia, FA, focal anaplasia

Excluding 6 patients who received either doxorubicin with no radiation or radiation with no doxorubicin

Log Rank test